Laser and thermal imaging developer Advanced Research Technologies (ART) of Montreal has received authorization from both Health Canada and the Ottawa Health Research Institute Ethics Board to begin a multicenter clinical trial for its SoftScan optical breast imaging device.
The study objective is to acquire biological data on a broad range of breast tissue, including targeted breast lesions. This data will be used in the final development of the SoftScan image processing system and will help to characterize the signatures of malignant and benign breast lesions for diagnostic purposes, the company said.
Imaging of up to 200 study volunteers at Ottawa Regional Women’s Breast Health Centre is expected to be concluded within the next year, according to ART. Dr. Nathalie Duchesne, radiologist and head of breast imaging and intervention at the center, will be acting as principal investigator of the trial.
By AuntMinnie.com staff writersSeptember 19, 2003
Related Reading
GE expands ART relationship, August 14, 2003
ART appoints Huot as CEO, September 14, 2001
ART closes $2 million private placement, July 11, 2001
ART scores $2 million investment, June 22, 2001
ART secures $7.5 million investment, June 13, 2001
Copyright © 2003 AuntMinnie.com
